Modified FOLFIRINOX ‘recommended adjuvant regimen’ for patients with pancreatic cancer

Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among patients with previously resected pancreatic ductal adenocarcinoma, according to 5-year data from a randomized phase 3 study.Results of the PRODIGE 24/Canadian Cancer Trials Group PA6 trial — published in JAMA Oncology showed improvement in DFS, OS, metastasis-free survival and cancer-specific survival across all predefined subgroups.Surgical excision of pancreatic ductal adenocarcinoma is potentially curative, but the 5-year OS rate for surgery alone is approximately 10%,Read More